Can impaired MTRR activity reduce homocysteine remethylation despite normal B12 markers?

The methionine synthase reductase (MTRR) enzyme is a critical governor of cellular methylation, responsible for maintaining the active state of vitamin B12.

Molecular mechanisms of B12 reactivation

• Reductive methylation cycle: MTRR acts as a dual-flavin NADPH-dependent oxidoreductase that transfers electrons to reduce inactive, oxidized cob(II)alamin to a highly reactive cob(I)alamin intermediate.
• Cofactor regeneration: S-adenosylmethionine (SAM) acts as a co-substrate to methylate this intermediate, regenerating active methylcobalamin directly on the methionine synthase (MTR) complex. This active cofactor is required to catalyze the transfer of a methyl group from 5-methyltetrahydrofolate to homocysteine, producing methionine.

Clinical and diagnostic implications

• Intracellular vs. systemic markers: Genetic variants that impair MTRR activity, such as MTRR A66G (rs1801394), reduce the rate of homocysteine remethylation. This localized, cytoplasmic deficiency can occur even when systemic markers like serum vitamin B12 and methylmalonic acid (MMA) are entirely normal, as MMA only reflects mitochondrial cobalamin-dependent mutase activity.
• Genetic synergy: The impact of impaired MTRR is significantly amplified when co-inherited with other folate pathway mutations, such as the MTHFR C677T variant, which synergistically elevates homocysteine levels.

Bottom line

• Bottom line: Impaired MTRR activity directly compromises intracellular vitamin B12 recycling and reduces homocysteine remethylation, creating a localized functional deficit that can elevate homocysteine levels despite completely normal serum B12 and methylmalonic acid markers.